Darbepoetin Administration to Preterm Infants
Completed · Phase 2 · Has a placebo group
Conditions studied: Infant, Newborn
In brief
Infants born prematurely do not increase production of the primary red cell growth factor, erythropoietin (Epo), and often develop an anemia called the "anemia of prematurity." The anemia of prematurity is the most common anemia seen in neonates, and is due to a failure of Epo production. Human recombinant Epo (rHuEpo), given three to five times a week, is successful in treating the anemia of prematurity. A slightly modified, long-acting version of rHuEpo, called darbepoetin alfa (darbepoetin), is now available and has proven effective in increasing hematocrit (red blood cell levels) in adults. In addition to its red cell stimulating properties, recent evidence has shown that rHuEpo is protective in the developing or injured brain. We have designed a randomized, masked, placebo-controlled study to determine the safety and short and long term efficacy of darbepoetin. At this time, darbepoetin has been studied primarily in adults and pediatric patients, but there is evidence from pilot studies that darbepoetin would be useful in the neonatal setting as well. It also may well improve neurodevelopmental outcomes in preterm neonates. We hypothesize that: 1. The administration of darbepoetin to preterm infants 500 to 1,250 grams birth weight will result in increased reticulocyte counts and decreased transfusions compared to placebo; and 2. The administration of darbepoetin will be associated with an increased mental developmental index at 18-22 months compared to placebo.
Key facts
- Study ID
- NCT00334737
- Run by
- University of New Mexico
- People needed
- 102
- Starts
- 2006-06-01
- Expected to finish
- 2014-06-01
- Last updated by the study team
- 2019-02-04
Who can join
Age: any, up to 0. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- 500-1250 grams birth weight
- less than or equal to 32 weeks gestation
- less than 2 days of age
You may not qualify if…
- severe hemorrhagic disease
- severe hemolytic disease
- DIC
- seizures
- hypertension
- thromboses
- receiving erythropoietin
Where it is running
- University of Colorado — Denver, Colorado, United States
- McKay-Dee Hospital — Ogden, Utah, United States
- LDS Hospital — Salt Lake City, Utah, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.